Axsome Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Axsome Therapeutics, Inc. on March 5, 2019. The filing details the entry into a material definitive agreement involving a new term loan facility and the issuance of unregistered equity securities (warrants) to lenders.
Key Financial Metrics and Debt Structure
- Total Facility Size: Up to $24,000,000 in aggregate principal amount.
- Initial Funding: $20,000,000 (Term A Loan Advance) funded on March 5, 2019.
- Contingent Funding: Up to $4,000,000 (Term B Loan Advance) available upon achieving a specific clinical milestone by August 15, 2019.
- Interest Rate: Floating rate equal to the greater of 7.50% or 2.0% above the prime rate.
- Maturity Date: February 1, 2023.
- Repayment Terms: Interest-only payments for 12 months (extendable to 18 months if Term B is funded), followed by monthly principal and interest payments.
- Collateral: First priority security interest in substantially all assets, excluding intellectual property and certain subsidiary equity interests.
Material Changes and Equity Issuance
The Company utilized a portion of the initial $20,000,000 advance to fully repay and extinguish obligations under a previously disclosed term loan facility with Silicon Valley Bank (SVB). In connection with the new agreement, the Company issued warrants to SVB and WestRiver Innovation Lending Fund VIII, L.P. to purchase common stock at an exercise price of $8.10 per share. The number of shares issuable is calculated based on the total loan advances funded relative to the $24,000,000 facility cap. These warrants are exercisable until March 5, 2026.
Outlook, Risks, and Covenants
The availability of the remaining $4,000,000 is contingent on the Company achieving positive data from its Phase 2 clinical trial for AXS-12 by August 15, 2019, sufficient to submit a Phase 3 protocol to the FDA without objection. The Loan Agreement includes restrictive covenants prohibiting the Company from incurring additional indebtedness, paying dividends, engaging in business combinations, or disposing of assets without consent. The filing references a press release regarding the Company's expected cash runway, though specific runway duration figures are not detailed in the text of this 8-K.
Investor Verification Checklist
- Verify the specific clinical data results for AXS-12 required to trigger the $4,000,000 Term B Loan Advance.
- Confirm the exact number of warrant shares issued based on the final funded loan amount.
- Review the full text of the Loan Agreement (Exhibit) for detailed covenant exceptions and default provisions.
- Check the referenced press release (Exhibit 99.1) for the specific duration of the Company's cash runway post-funding.
- Monitor the Company's ability to meet the August 15, 2019, milestone to avoid potential liquidity constraints.